BRAF and melanoma: This study focused on preventing the increased invasive migration of BRAFi‐R melanoma cells; however, our combined treatment with an IL‐6 antibody and Box5 also restored the sensitivity of these cells to the BRAF inhibitor PLX4032 (Fig. S7A–D).